Oruka Therapeutics, Inc.

Contributing Author

Recent Articles by Oruka Therapeutics, Inc.

Aug-11	Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update ORKA GlobeNewswire
Jul-21	Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September ORKA GlobeNewswire
Jul-01	Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer ORKA GlobeNewswire
May-21	Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference ORKA GlobeNewswire
May-20	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody ORKA GlobeNewswire
May-14	Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update ORKA GlobeNewswire